Skip to content

Harmonic ACE®+7 Shears in Laparoscopic Colectomy

Prospective, Multicenter, Observational Study Evaluating Vessel Sealing Utilizing the Harmonic ACE®+7 Shears During Laparoscopic Colectomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02248246
Enrollment
40
Registered
2014-09-25
Start date
2014-08-31
Completion date
2015-06-30
Last updated
2016-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign or Malignant Disease Indicated for Colectomy

Keywords

Hemostasis, Harmonic ACE®+7 Shears, Laparoscopic, Inferior mesenteric artery, Inferior mesenteric vein, Observational

Brief summary

This is a prospective, non-randomized, single arm, multicenter, observational study to assess the initial clinical experience with the Harmonic ACE®+7 Shears by evaluating vessel sealing during laparoscopic colectomy. The study will not modify or influence current surgeon technique. Investigators will perform each procedure using the device in compliance with their standard surgical approach and product labeling. The Harmonic ACE®+7 Shears is cleared for commercial distribution and will be used in accordance with approved product labeling. The Harmonic ACE®+7 Shears will be assembled, calibrated, and/or used in accordance with manufacturer design specifications, product instructions and guidelines.

Detailed description

Study Population: Subjects enrolled into this study will undergo elective laparoscopic colectomy wherein dissection and transection of the (inferior mesenteric artery) IMA is indicated. Primary Variable: Incidence of hemostasis at the IMA Secondary Endpoint: Incidence of hemostasis at the inferior mesenteric vain (IMV). Definition: Hemostasis of the IMA and IMV is a dichotomous variable (i.e. yes or no). Yes is defined as a single activation of the Advanced Hemostasis Mode to transect and seal the IMA and IMV. Additional exploratory endpoints include: The percentage of subjects requiring additional measures to obtain hemostasis on the IMA and/or IMV, if identified: * Number of Harmonic touch ups - frequency of Harmonic reapplications required due to oozing or bleeding at initial transection of named vessels * Use of other energy devices (tissue sealers, cautery devices) - Graded as yes or no; if yes, the type, transection time (using stopwatch), time of application (24 hour clock) * Use of hemostatic products (e.g. hemoclips, staples, sutures, fibrin sealants) - Graded as yes or no; if yes, the type and name of product, number/volume, and time of application (24 hour clock) Summary of the use of additional treatment after first pass hemostasis has already been achieved at the IMA and IMV. Graded as yes or no; if yes, the type, number/volume, time of application (24 hour clock) and rationale for use. Adverse events attributed to the study device or procedure will be collected from time of surgery to Visit 4 (Approximately 4 weeks after study surgery or as per standard of care (SOC)). Sample size: No formal sample size determination is required for this study. Approximately 40 subjects from the United States and the European Union are planned to be enrolled into this study. Global indication for use of the The Harmonic ACE®+7, 5mm Diameter Shears with Advanced Hemostasis: Indicated for soft tissue incisions when bleeding control and minimal thermal injury are desired. The instruments can be used as an adjunct to or substitute for electrosurgery, lasers and steel scalpels in general, plastic, pediatric, gynecologic, urologic, thoracic, exposure to orthopedic structures (such as spine and joint space), sealing and transection of lymphatic vessels, and other open and endoscopic procedures. The instruments allow for the coagulation of vessels up to and including 7mm in diameter, using the Advanced Hemostasis function.

Interventions

Vessel sealing performance assessed for transection and sealing of the following named vessels: * Inferior mesenteric artery (IMA) * Inferior mesenteric vein (IMV) (if identified)

Sponsors

Ethicon Endo-Surgery
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Indicated for elective laparoscopic colectomy 2. Planned dissection and transection of the IMA 3. Age: equal to or more than18 years

Exclusion criteria

Preoperative

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Participants With Hemostasis at the IMAIntraoperativelyHemostasis of the IMA is a dichotomous variable (i.e. yes or no). Yes is defined as a single activation of the Advanced Hemostasis Mode to transect and seal the IMA.

Secondary

MeasureTime frameDescription
Percentage of Participants With Hemostasis at the IMVIntraoperativelyHemostasis of the IMV is a dichotomous variable (i.e. yes or no). Yes is defined as a single activation of the Advanced Hemostasis Mode to transect and seal the IMV.

Countries

Belgium, United Kingdom, United States

Participant flow

Participants by arm

ArmCount
Colectomy With Harmonic ACE®+7 Shears
Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection Harmonic ACE®+7 Shears: Vessel sealing performance assessed for transection and sealing of the following named vessels: * Inferior mesenteric artery (IMA) * Inferior mesenteric vein (IMV) (if identified)
40
Total40

Baseline characteristics

CharacteristicColectomy With Harmonic ACE®+7 Shears
Age, Continuous59.8 years
STANDARD_DEVIATION 13.3
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
40 Participants
Region of Enrollment
Belgium
15 participants
Region of Enrollment
United Kingdom
11 participants
Region of Enrollment
United States
14 participants
Sex: Female, Male
Female
24 Participants
Sex: Female, Male
Male
16 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
20 / 40
serious
Total, serious adverse events
5 / 40

Outcome results

Primary

Percentage of Participants With Hemostasis at the IMA

Hemostasis of the IMA is a dichotomous variable (i.e. yes or no). Yes is defined as a single activation of the Advanced Hemostasis Mode to transect and seal the IMA.

Time frame: Intraoperatively

Population: Safety Set - all subjects in whom the procedure was started.

ArmMeasureValue (NUMBER)
Colectomy With Harmonic ACE®+7 ShearsPercentage of Participants With Hemostasis at the IMA100.0 percentage of subjects
Secondary

Percentage of Participants With Hemostasis at the IMV

Hemostasis of the IMV is a dichotomous variable (i.e. yes or no). Yes is defined as a single activation of the Advanced Hemostasis Mode to transect and seal the IMV.

Time frame: Intraoperatively

Population: Safety Set - all subjects in whom the procedure was started.

ArmMeasureValue (NUMBER)
Colectomy With Harmonic ACE®+7 ShearsPercentage of Participants With Hemostasis at the IMV97.5 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026